Filtered By:
Cancer: Lymphoma
Infectious Disease: Pandemics
This page shows you your search results in order of date.
Order by Relevance | Date
Total 164 results found since Jan 2013.
Nine-year Follow-up of Lenalidomide Plus Rituximab as Initial Treatment for Mantle Cell Lymphoma
We report 9-year follow up of a multi-center phase 2 study of lenalidomide plus rituximab (LR) as initial treatment of MCL. The LR doublet is used as induction and maintenance until progression, with optional discontinuation after 3 years. We previously reported an overall response rate in evaluable patients of 92%, with 64% achieving a complete response. At a median follow up of 103 months, 17 (47%) of 36 evaluable patients remain in remission. The 9-year progression-free survival (PFS) and overall survival (OS) were 51% and 66%, respectively. During maintenance, hematologic adverse events (AEs) included asymptomatic grad...
Source: Adv Data - September 8, 2023 Category: Epidemiology Authors: Samuel Yamshon Gui Chen Caitlin Gribbin Paul Christos Bijal D Shah Stephen J Schuster Sonali M Smith Jakub Svoboda Richard R Furman John P Leonard Peter Martin Jia Ruan Source Type: research
Impact of T-cell Engagers on COVID-19-related Mortality in B-cell Lymphoma Patients Receiving B-cell Depleting Therapy
CONCLUSION: B-cell lymphoma patients treated with TCE had significantly worse outcomes from COVID-19 than those treated with RTX. TCE therapy should be used with caution in B-cell lymphoma patients during the COVID-19 epidemic.PMID:37448122 | DOI:10.4143/crt.2023.738
Source: Cell Research - July 14, 2023 Category: Cytology Authors: Chan Mi Lee Pyoeng Gyun Choe Chang Kyung Kang Hyeon Jae Jo Nam Joong Kim Sung-Soo Yoon Tae Min Kim Wan Beom Park Myoung-Don Oh Source Type: research
Impact of the COVID-19 pandemic on cancer diagnoses, stage and survival in Alberta
In this study, we evaluated the impact of the state of emergency period during the COVID-19 pandemic (Mar. 17 to June 15, 2020) on cancer diagnoses, stage at diagnosis and 1-year survival in Alberta.METHODS: We included new diagnoses of the 10 most prevalent cancer types from Jan. 1, 2018, to Dec. 31, 2020. We followed patients up to Dec. 31, 2021. We used interrupted time series analysis to examine the impact of the first COVID-19-related state of emergency in Alberta on the number of cancer diagnoses. We used multivariable Cox regression to compare 1-year survival of the patients who received a diagnosis during 2020 afte...
Source: cmaj - June 12, 2023 Category: General Medicine Authors: Emily Heer Yibing Ruan Devon J Boyne Tamer N Jarada Daniel Heng Jan-Willem Henning Donald M Morris Dylan E O'Sullivan Winson Y Cheung Darren R Brenner Source Type: research
Clinical Outcomes in Patients With COVID-19 and Hematologic Disease
CONCLUSION: Patients with hematologic disease and COVID-19 have high mortality rates, predominantly due to COVID-19 complications. At a longer-term follow-up, no significant impact of COVID-19 on the course of a hematologic disease was revealed.PMID:37236904 | PMC:PMC10102503 | DOI:10.1016/j.clml.2023.04.002
Source: Clinical Lymphoma and Myeloma - May 26, 2023 Category: Cancer & Oncology Authors: Olga A Aleshina Kristina Zakurdaeva Anastasia N Vasileva Sergey K Dubov Vitaly S Dubov Vladimir I Vorobyev Lev S Butaev Alena M Sukhareva Lubov V Gavrilova Inessa Yu Toropova Marina O Popova Aleksandr A Siniaev Aleksandr D Kulagin Kamil D Kaplanov Andrei Source Type: research
A Phase II, Open-Label Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma
CONCLUSION: This is the first formal prospective trial using infusion times shorter than the standard schedule directly after an initial 4-hours dose. This rapid infusion protocol has resulted in more efficient resource utilization and has become the standard protocol for the use in all intravenous daratumumab regimens in Canada. This approach has been particularly helpful in shortening chair time during the COVID-19 pandemic and providing a useful alternative in jurisdictions without access to subcutaneous daratumumab.PMID:37127473 | DOI:10.1016/j.clml.2023.03.006
Source: Clinical Lymphoma and Myeloma - May 1, 2023 Category: Cancer & Oncology Authors: Julie Stakiw Shruthi Kodad Richard LeBlanc Michael Sebag Annette E Hay Vishal Kukreti Julie C ôté Fernando Camacho Molei Fu Engin Gul Donna Reece Source Type: research
A Clinical and Correlative Study of Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd) for Lenalidomide Refractory Multiple Myeloma in First Relapse
CONCLUSION: A short course of Elo-KRd induction followed by Elo-lenalidomide maintenance demonstrated activity in predominantly lenalidomide-refractory and / or high-risk MM. The results with this well-tolerated combination are comparable to other contemporary approved triplet combinations.PMID:37127471 | DOI:10.1016/j.clml.2023.03.016
Source: Clinical Lymphoma and Myeloma - May 1, 2023 Category: Cancer & Oncology Authors: Manisha Bhutani David M Foureau Myra Robinson Fei Guo Kateryna Fesenkova Shebli Atrash Barry Paul Cindy Varga Reed Friend Mauricio Pineda-Roman Katherine Rigby James T Symanowski Sarah Norek Mallory R Tucker Lawrence J Druhan Peter M Voorhees Saad Z Usman Source Type: research
A Phase II, Open-Label Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma
CONCLUSION: This is the first formal prospective trial using infusion times shorter than the standard schedule directly after an initial 4-hours dose. This rapid infusion protocol has resulted in more efficient resource utilization and has become the standard protocol for the use in all intravenous daratumumab regimens in Canada. This approach has been particularly helpful in shortening chair time during the COVID-19 pandemic and providing a useful alternative in jurisdictions without access to subcutaneous daratumumab.PMID:37127473 | DOI:10.1016/j.clml.2023.03.006
Source: Clinical Lymphoma and Myeloma - May 1, 2023 Category: Cancer & Oncology Authors: Julie Stakiw Shruthi Kodad Richard LeBlanc Michael Sebag Annette E Hay Vishal Kukreti Julie C ôté Fernando Camacho Molei Fu Engin Gul Donna Reece Source Type: research
A Clinical and Correlative Study of Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd) for Lenalidomide Refractory Multiple Myeloma in First Relapse
CONCLUSION: A short course of Elo-KRd induction followed by Elo-lenalidomide maintenance demonstrated activity in predominantly lenalidomide-refractory and / or high-risk MM. The results with this well-tolerated combination are comparable to other contemporary approved triplet combinations.PMID:37127471 | DOI:10.1016/j.clml.2023.03.016
Source: Clinical Lymphoma and Myeloma - May 1, 2023 Category: Cancer & Oncology Authors: Manisha Bhutani David M Foureau Myra Robinson Fei Guo Kateryna Fesenkova Shebli Atrash Barry Paul Cindy Varga Reed Friend Mauricio Pineda-Roman Katherine Rigby James T Symanowski Sarah Norek Mallory R Tucker Lawrence J Druhan Peter M Voorhees Saad Z Usman Source Type: research
A Phase II, Open-Label Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma
CONCLUSION: This is the first formal prospective trial using infusion times shorter than the standard schedule directly after an initial 4-hours dose. This rapid infusion protocol has resulted in more efficient resource utilization and has become the standard protocol for the use in all intravenous daratumumab regimens in Canada. This approach has been particularly helpful in shortening chair time during the COVID-19 pandemic and providing a useful alternative in jurisdictions without access to subcutaneous daratumumab.PMID:37127473 | DOI:10.1016/j.clml.2023.03.006
Source: Clinical Lymphoma and Myeloma - May 1, 2023 Category: Cancer & Oncology Authors: Julie Stakiw Shruthi Kodad Richard LeBlanc Michael Sebag Annette E Hay Vishal Kukreti Julie C ôté Fernando Camacho Molei Fu Engin Gul Donna Reece Source Type: research
A Clinical and Correlative Study of Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd) for Lenalidomide Refractory Multiple Myeloma in First Relapse
CONCLUSION: A short course of Elo-KRd induction followed by Elo-lenalidomide maintenance demonstrated activity in predominantly lenalidomide-refractory and / or high-risk MM. The results with this well-tolerated combination are comparable to other contemporary approved triplet combinations.PMID:37127471 | DOI:10.1016/j.clml.2023.03.016
Source: Clinical Lymphoma and Myeloma - May 1, 2023 Category: Cancer & Oncology Authors: Manisha Bhutani David M Foureau Myra Robinson Fei Guo Kateryna Fesenkova Shebli Atrash Barry Paul Cindy Varga Reed Friend Mauricio Pineda-Roman Katherine Rigby James T Symanowski Sarah Norek Mallory R Tucker Lawrence J Druhan Peter M Voorhees Saad Z Usman Source Type: research
Newly diagnosed extranodal NK/T-cell lymphoma, nasal type, at the injected left arm after BNT162b2 mRNA COVID-19 vaccination
Int J Hematol. 2023 Apr 24. doi: 10.1007/s12185-023-03607-w. Online ahead of print.ABSTRACTAnti-SARS-CoV-2 vaccines were developed in response to the coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although the BNT162b2 mRNA vaccine is effective, adverse effects have been reported. Here, we report a case of extranodal NK/T-cell lymphoma, nasal type (ENKL), of the left arm following BNT162b2 mRNA vaccination. A 73-year-old male presented with a lump in the left arm, which was the site where he received the BNT162b2 mRNA vaccine 3 months prior. He was treat...
Source: International Journal of Hematology - April 24, 2023 Category: Hematology Authors: Takuto Tachita Takenori Takahata Satoru Yamashita Toru Ebina Kosuke Kamata Kazufumi Yamagata Yoshiko Tamai Hirotake Sakuraba Source Type: research
